Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
Switzerland
Regulatory Approval:
N/A
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Zynlonta (loncastuximab tesirine-lpyl) is an antibody-drug conjugate approved by the FDA under accelerated approval for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL) after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low-grade lymphoma, and high-grade B-cell lymphoma.
Zynlonta combines a monoclonal antibody targeting CD19, a protein found on B-cell lymphoma cells, with a potent DNA-damaging payload. Once bound to CD19, Zynlonta is internalized by the cancer cell, releasing the payload to induce cancer cell death.
Zynlonta is intended for patients with relapsed or refractory large B-cell lymphoma who have already received at least two prior lines of systemic therapy, offering a targeted option for this heavily pretreated population.
Zynlonta is administered as an intravenous infusion over 30 minutes, at 0.15 mg/kg every 3 weeks for the first 2 cycles, then 0.075 mg/kg every 3 weeks for subsequent cycles, with dexamethasone premedication given before each dose to help reduce infusion-related and fluid-related side effects.
Zynlonta does not carry a formal FDA boxed warning. However, patients and prescribers should be aware of the following important safety information.
Effusion and edema, including capillary leak syndrome, pleural effusion, and pericardial effusion, have been reported, in some cases severe. Patients should be monitored for fluid retention and managed with premedication and supportive care.
Low blood cell counts, including neutropenia, thrombocytopenia, and anemia, are common. Complete blood counts should be monitored throughout treatment.
Serious infections and liver enzyme elevations, including drug-induced liver injury, have been reported. Liver function should be monitored during treatment.
Skin reactions have been observed. Zynlonta may also cause fetal harm; effective contraception should be used during treatment and for a period after the final dose.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Zynlonta is manufactured and marketed by ADC Therapeutics SA. It is sourced through authorized distribution channels for patients seeking named-patient import into India.
Patients typically need a valid prescription from a treating hematologist-oncologist confirming large B-cell lymphoma diagnosis and prior treatment history. NPP's regulatory team assists in preparing and verifying the documentation needed for a compliant import.
As an FDA-approved therapy for relapsed or refractory large B-cell lymphoma, Zynlonta is sourced through authorized channels and imported under GDP-compliant, cold-chain logistics to preserve product quality throughout transit.
NPP sources Zynlonta directly from authorized pharmaceutical distributors to ensure product authenticity and full traceability. Every shipment is handled under Good Distribution Practice (GDP) conditions from origin to the patient's doorstep.
Zynlonta requires refrigerated storage at 2°C to 8°C in its original carton, protected from light, and must not be frozen or shaken. NPP maintains a continuous, monitored cold chain throughout transit.
Once documentation and regulatory approvals are in place, delivery timelines are communicated transparently at the time of quotation, accounting for import clearance and last-mile cold-chain logistics to the patient's city.
Patients across India can access Zynlonta through NPP's regulated import pathway, with hematology-oncology specialists in major cities supporting the treatment process.
Leading hospitals in Mumbai support hematology-oncology care coordination and documentation for Zynlonta access.
Delhi's major hospitals assist patients with prescription support and documentation for Zynlonta.
Bangalore's specialist network offers access coordination for eligible lymphoma patients seeking Zynlonta.
Chennai-based hematology specialists coordinate Zynlonta access alongside comprehensive lymphoma care.
Hyderabad's care institutions support patients pursuing Zynlonta therapy.
Kolkata's specialist centers help coordinate documentation and treatment access for Zynlonta.
Pune-based specialists assist with prescription support and Zynlonta treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Zynlonta.
Kochi's specialist units assist patients with the documentation needed for Zynlonta access.
Chandigarh's care centers support Zynlonta treatment coordination for patients from North India.
Jaipur's specialists help patients navigate the Zynlonta access process.
Lucknow-based centers assist patients pursuing Zynlonta therapy.
Bhubaneswar's institutions support access to Zynlonta for eligible patients.
Guwahati's specialists help coordinate Zynlonta access for patients across the Northeast.
Patients in other cities across India can also access Zynlonta through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 15 September 2026
Sources: FDA
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 15 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
